On the other hand, the discovery of immune checkpoint inhibitors, such as anti-PD-1 (programmed cell delath protein 1) and anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4, CD152) antibodies, has shown improved patient outcomes for numerous cancers, including CRC [4,5,6]. This evidence concerns the gene CTLA4 and cancer.